Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes

Youk, Ji Hyun; Son, Eun Ju; Chung, Jin; Kim, Jeong Ah; Kim, Min Jung

doi:10.1007/s00330-012-2425-2

Cited by 200 publications

(174 citation statements)

References 40 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…Kim and colleagues did not find a relation between HER2 status and initial slope, peak enhancement, time to peak enhancement, or washout ratio (76). Lee and colleagues found no relation between initial slope and HER2 status (79), and Youk and colleagues found no relation between early-phase percentage enhancement and HER2 status (92). Again following Figure 4.…”

Section: Mri Features In Relation To Her2 Overexpression In Breast Camentioning

confidence: 96%

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

Elias

Adams

Wisner

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Breast cancer imaging phenotype is diverse and may relate to molecular alterations driving cancer behavior. We systematically reviewed and meta-analyzed relations between breast cancer imaging features and human epidermal growth factor receptor type 2 (HER2) overexpression as a marker of breast cancer aggressiveness. MEDLINE and EMBASE were searched for mammography, breast ultrasound, magnetic resonance imaging (MRI), and/or [ 18 F]fluorodeoxyglucose positron emission tomography studies through February 2013. Of 68 imaging features that could be pooled (85 articles, 23,255 cancers; random-effects meta-analysis), 11 significantly related to HER2 overexpression. Results based on five or more studies and robustness in subgroup analyses were as follows: the presence of microcalcifications on mammography [pooled odds ratio (pOR), 3.14; 95% confidence interval (CI), 2.46-4.00] or ultrasound (mass-associated pOR, 2.95; 95% CI, 2.34-3.71), branching or fine linear microcalcifications (pOR, 2.11; 95% CI, 1.07-4.14) or extremely dense breasts on mammography (pOR, 1.37; 95% CI, 1.07-1.76), and washout (pOR, 1.57; 95% CI, 1.11-2.21) or fast initial kinetics (pOR, 2.60; 95% CI, 1.43-4.73) on MRI all increased the chance of HER2 overexpression. Maximum [ 18 F]fluorodeoxyglucose standardized uptake value (SUV max ) was higher upon HER2 overexpression (pooled mean difference, þ0.76; 95% CI, 0.10-1.42). These results show that several imaging features relate to HER2 overexpression, lending credibility to the hypothesis that imaging phenotype reflects cancer behavior. This implies prognostic relevance, which is especially relevant as imaging is readily available during diagnostic work-up. Cancer Epidemiol Biomarkers Prev; 23(8); 1464-83. Ó2014 AACR.

show abstract

Section: Mri Features In Relation To Her2 Overexpression In Breast Camentioning

confidence: 96%

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

Elias

Adams

Wisner

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Several reports have compared diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) values in addition to the morphological characteristics on MRI with various pathological findings and biomarkers of breast cancer [6][7][8][9][10][11] . The ADC reflects the microenvironment of the tissue structures and is therefore related to the malignant features, such as cellularity, of the tumor.…”

Section: Introductionmentioning

confidence: 99%

Differences in morphological features and minimum apparent diffusion coefficient values among breast cancer subtypes using 3-tesla MRI

Kato

Kudo

Yamashita

et al. 2016

European Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…Indeed, the impact of multimodal MRI-including screening protocols on patient outcome of high-risk women is under consideration (24,35,36). Furthermore, multimodal imaging to screen high-risk women can currently exploit the imaging phenotypes of familial breast cancer (37), with peculiar MRI characteristics of TNBCs (38,39).…”

Section: Discussionmentioning

confidence: 99%

Triple-Negative versus Non–Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study

Podo

Santoro

Leo

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To compare phenotype features and survival of triple-negative breast cancers (TNBC) versus non-TNBCs detected during a multimodal annual screening of high-risk women.Experimental Design: Analysis of data from asymptomatic high-risk women diagnosed with invasive breast cancer during the HIBCRIT-1 study with median 9.7-year follow-up.Results: Of 501 enrolled women with BRCA1/2 mutation or strong family history (SFH), 44 were diagnosed with invasive breast cancers: 20 BRCA1 (45%), 9 BRCA2 (21%), 15 SFH (34%). Magnetic resonance imaging (MRI) sensitivity (90%) outperformed that of mammography (43%, P < 0.001) and ultrasonography (61%, P ¼ 0.004). The 44 cases (41 screen-detected; 3 BRCA1-associated interval TNBCs) comprised 14 TNBCs (32%) and 30 non-TNBCs (68%), without significant differences for age at diagnosis, menopausal status, prophylactic oophorectomy, or previous breast cancer. Of 14 TNBC patients, 11 (79%) were BRCA1; of the 20 BRCA1 patients, 11 (55%) had TNBC; and of 15 SFH patients, 14 (93%) had non-TNBCs (P ¼ 0.007). Invasive ductal carcinomas (IDC) were 86% for TNBCs versus 43% for non-TNBCs (P ¼ 0.010), G3 IDCs 71% versus 23% (P ¼ 0.006), size 16 AE 5 mm versus 12 AE 6 mm (P ¼ 0.007). TNBC patients had more frequent ipsilateral mastectomy (79% vs. 43% for nonTNBCs, P ¼ 0.050), contralateral prophylactic mastectomy (43% vs. 10%, P ¼ 0.019), and adjuvant chemotherapy (100% vs. 44%, P < 0.001). The 5-year overall survival was 86% AE 9% for TNBCs versus 93% AE 5% (P ¼ 0.946) for non-TNBCs; 5-year disease-free survival was 77% AE 12% versus 76% AE 8% (P ¼ 0.216).Conclusions: In high-risk women, by combining an MRIincluding annual screening with adequate treatment, the usual reported gap in outcome between TNBCs and non-TNBCs could be reduced. Clin Cancer Res; 22(4); 895-904. Ó2015 AACR.

show abstract

Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes

Cited by 200 publications

References 40 publications

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

Differences in morphological features and minimum apparent diffusion coefficient values among breast cancer subtypes using 3-tesla MRI

Triple-Negative versus Non–Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study

Contact Info

Product

Resources

About